From August 24, 2023 to September 30, 2023, the company has repurchased 533,100 shares, representing 0.49% for CNY 34.05 million. With this, the company has completed the repurchase of 533,100 shares, representing 0.49% for CNY 34.05 million under the buyback announced on August 24, 2023.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
Equities
301096
CNE1000056N5
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
60.13 CNY | -3.17% | -1.91% | -7.63% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.63% | 898M | |
+55.55% | 59.28B | |
+42.83% | 40.94B | |
-4.71% | 40.17B | |
-5.56% | 28.69B | |
+13.76% | 26.63B | |
-22.00% | 18.89B | |
+31.50% | 12.46B | |
+2.16% | 12.42B | |
+25.70% | 12.26B |
- Stock Market
- Equities
- 301096 Stock
- News Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
- Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023.